Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma

Intern Med. 2021 Feb 15;60(4):545-552. doi: 10.2169/internalmedicine.5097-20. Epub 2020 Oct 7.

Abstract

An 82-year-old man with hepatocellular carcinoma presented with upper abdominal pain, vomiting, and jaundice. He had been taking a standard lenvatinib dose for three months. Although acute cholangitis was suggested, imaging studies failed to detect the biliary obstruction site. An endoscopic examination following discontinuation of lenvatinib and aspirin revealed multiple duodenal ulcers, one of which was formed on the ampulla of Vater and causing cholestasis. Endoscopic biliary drainage and antibiotics improved concomitant Enterobacter cloacae bacteremia. Ulcer healing was confirmed after rabeprazole was replaced with vonoprazan and misoprostol. Our case shows that lenvatinib can induce duodenal ulcers resulting in obstructive jaundice.

Keywords: aspirin; duodenal ulcer; hepatocellular carcinoma; lenvatinib; obstructive jaundice.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Carcinoma, Hepatocellular* / drug therapy
  • Duodenal Ulcer* / chemically induced
  • Duodenal Ulcer* / diagnosis
  • Humans
  • Jaundice, Obstructive* / chemically induced
  • Liver Neoplasms* / drug therapy
  • Male
  • Phenylurea Compounds
  • Quinolines

Substances

  • Phenylurea Compounds
  • Quinolines
  • lenvatinib